Author

A. C. Villani

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

N. Hacohen· 2 shared A. L. K. Gonye· 1 shared A. Sonny· 1 shared A. Veillette· 1 shared B. A. Parry· 1 shared B. C. Russo· 1 shared B. M. Lilly· 1 shared B. N. Mckaig· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

N. Hacohen

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients

T. J. LaSalle, A. L. K. Gonye, S. S. Freeman, P. Kaplonek, I. Gushterova, K. R. Kays, K. Manakongtreecheep, J. Tantivit, M. Rojas-Lopez, B. C. Russo, N. Sharma, M. F. Thomas, K. M. Lavin-Parsons, B. M. Lilly, B. N. Mckaig, , M. Sade-Feldman

This study identifies distinct neutrophil phenotypes linked to disease severity in hospitalized COVID-19 patients using longitudinal data and multi-omics analyses.

Cell Reports Medicine · Oct 1, 2022Peer-reviewedImmunology

SLAMF6 deficiency augments tumor killing and skews towards an effector phenotype revealing it as a new T cell checkpoint

E. Hajaj, G. Eisenberg, S. Klein, S. Frankenburg, S. Merims, I. Ben David, T. Eisenhaure, S. E. Henrickson, A. C. Villani, N. Hacohen, N. Abudi, R. Abramovich, J. E. Cohen, T. Peretz, A. Veillette, M. Lotem

This study shows that SLAMF6 deficiency enhances T cell tumor-killing ability and shifts T cells toward an effector phenotype, suggesting SLAMF6 as a new immune checkpoint.

bioRxiv · Oct 31, 2019Physiology